Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI

This article was originally published in The Tan Sheet

Executive Summary

Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.

Advertisement

Related Content

Perrigo Nutritional Portfolio Grows As Supplement Business Sale Proceeds
Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play
Mylan Stretches Game Clock, Adds To Costs For Perrigo Takeover Play
Dr. Reddy’s Competition For Perrigo’s Omeprazole Delayed Six Months

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS107828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel